
	
Curriculum vitae Europass	
Personal information	
Name / Surname	Trifa Adrian Pavel
Date of birth	9.11.1985
E-mail address	adrian.trifa@umft.ro ; adrian.trifa@umft.ro
Nationality	Romanian
Work experience	
Dates	from Apr. 2023 onwards
Position held	Senior Consultant in Medical Genetics
Main activities and responsibilities	Genetic testing and counseling patients with solid malignancies and hereditary respiratory diseases
Employer's name and address	"Victor Babes" Hospital, 13, Gheorghe Adam St, Timișoara, Romania
Type of business	Health and research
Dates	from Oct. 2022 onwards
Position held	Assoc. Prof., then Prof., Medical Genetics Department
Main activities and responsibilities	Genetics courses for Medical and Dentistry students; PhD students coordination, research projects; member in the Scientific Committee of the "Victor Babes" University of Medicine and Pharmacy
Employer's name and address	"Victor Babes" University of Medicine and Pharmacy, 2, Piața Eftimie Murgu, Timișoara, Romania
Type of business	Education and research
Dates	2011-sept 2022
Position held	Assist. prof, then Assoc. prof., Medical Genetics Department
Main activities and responsibilities	Genetics courses for Medical and Dentistry students (Romanian and French sections), research projects
Employer's name and address	"Iuliu Hatieganu" University of Medicine and Pharmacy; 8, Victor Babeș St., 400012, Cluj-Napoca, Romania
Type of business	Education and research

Dates	from March 2015 onwards
Position held	Consultant, then Senior Consultant in Medical Genetics
Main activities and responsibilities	Molecular diagnosis in solid tumors and hematological malignancies, genetic counseling for hereditary cancer patients, research projects.
Employer's name and address	„Prof. Dr. I. Chiricuta” Cancer Institute, Str. Republicii 34-36, Cluj-Napoca, Romania
Type of business	Health, research
Dates	January 2011-December 2014
Position held	Resident physician in Medical Genetics
Main activities and responsibilities	Genetic diagnosis and genetic counselling in genetic diseases
Employer's name and address	Cluj County Emergency Hospital, Cluj-Napoca, Romania
Type of business	Health
Dates	October 2007-December 2010
Position held	Research assistant
Main activities and responsibilities	Molecular genetics techniques in four national research projects
Employer's name and address	"Iuliu Hatieganu” University of Medicine and Pharmacy; 8, Victor Babeş St., 400012, Cluj-Napoca, Romania
Type of business	Research
Education and training	
Dates	Oct 2021
Qualification awarded	Dr. Habil. Habilitation thesis title: Genetic factors involved in the occurrence of hematological malignancies and hemostatic disorders
Education or training organisation's name and locality (if relevant, country)	Iuliu Hatieganu” University of Medicine and Pharmacy; 8, Victor Babeş St., 400012, Cluj-Napoca, Romania
Dates	October 2010-July 2014
Qualification awarded	PhD in Medicine. PhD thesis title: Genetic factors involved in the occurrence of non-BCR-ABL myeloproliferative neoplasms and their thrombotic complications
Education or training organisation's name and locality (if relevant, country)	"Iuliu Hatieganu” University of Medicine and Pharmacy; 8, Victor Babeş St., 400012, Cluj-Napoca, Romania

Dates	October 2004-September 2010
Qualification awarded	MD
Education or training organisation's name and locality (if relevant, country)	"Iuliu Hatieganu" University of Medicine and Pharmacy; 8, Victor Babeş St., 400012, Cluj-Napoca, Romania
Dates	September 2000-June 2004
Qualification awarded	Bachelor degree in science
Education or training organisation's name and locality (if relevant, country)	"Iosif Vulcan" Highschool, Oradea, Romania
Courses	
Dates	July-August 2023
Qualification awarded	Clinical use of germline and somatic genetic testing in oncological patients
Education or training organisation's name and locality (if relevant, country)	Vanderbilt University Medical Center, Nashville, USA
Dates	March 2018
Qualification awarded	Sequencing techniques for analysing various mutations in myeloid neoplasms
Education or training organisation's name and locality (if relevant, country)	Henri Becquerel Institute, Rouen, France
Dates	March and August 2015
Qualification awarded	FISH in solid tumors
Education or training organisation's name and locality (if relevant, country)	„Prof. Dr. I. Chiricuta” Cancer Institute , Cluj-Napoca, Romania
Dates	May 2008
Qualification awarded	FISH in post-natal diagnosis
Education or training organisation's name and locality (if relevant, country)	„Victor Babeş” University of Medicine and Pharmacy, Timișoara, Romania
Dates	September 2006
Qualification awarded	The impact of genetics in human pathology

Education or training organisation's name and locality (if relevant, country)	„Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania				
Memberships	<ol style="list-style-type: none"> 1. European Society of Human Genetics (ESHG) 2. European Society of Medical Oncology (ESMO) 3. Romanian Society of Medical Genetics 4. Romanian Society of Radiation Therapy and Medical Oncology 				
Personal skills					
Mother tongue	Romanian				
Other languages					
	Understanding		Speaking		Writing
<i>European level (*)</i>	Reading	Spoken interaction	Spoken production	Reading	Spoken interaction
French DALF (Diplôme Approfondi de Langue Française) from 2004	C1	C1	C1	C1	C1
English	C1	C1	C1	C1	C1
Italian	A2	A2	A2	A2	A2
German	A2	A2	A2	A2	A2
	(*)Levels: A1/A2: Basic user - B1/B2: Independent user - C1/C2 Proficient user Common European Framework of Reference for Languages				

Professional and organisational skills	<p>I was involved in 18 projects (2 international and 16 national). In 4 of them I was principal investigator – see annexe 1.</p> <p>I published over 65 articles in ISI journals. They were cited over 1500 times so far; my current Hirsh index is 23 (Google Scholar), and 16 (Scopus and ISI Web of Knowledge).</p> <p>My publication list can be consulted here: https://pubmed.ncbi.nlm.nih.gov/?term=trifa+adrian&sort=date</p> <p>I am founder and president of the humanitarian association "Noi pentru EI (NEI)", that helps financially patients which don't afford the costs of genetic tests.</p>

Annexe 1 Research projects

National projects – principal investigator

1. The impact of the constitutional variation at the TERT, TET2 and MYB/HBS1L loci on the occurrence of the non-BCR-ABL myeloproliferative neoplasms, MYELOGEN, TE (Tinere Echipe) grant, dates: 2015-2017
2. Assessing the combined effect of multiple polymorphisms in order to define the genetic predisposition to myeloproliferative neoplasms, PD (post-doctoral) grant, dates 2018-2020
3. Next generation sequencing - a valuable tool for assessing the impact of additional somatic mutations in young patients with non-BCR-ABL myeloproliferative neoplasms, TE (Tinere Echipe) grant, dates: 2020-2022
4. The predictive value of JAK2 V617F and CALR mutations allele burden in the occurrence of thrombosis and secondary myelofibrosis in polycythemia vera and essential thrombocythemia, "Iuliu Hatieganu" University of Medicine and Pharmacy project, dates 2016-2017

National projects - member

1. Using molecular and cytogenetic methods for evaluating the genetic causes of reproductive failure in Romania, in order to improve genetic counselling and prophylaxis, type A CNCSIS project, principal investigator Dr. Victor Pop, dates 2007-2008
2. Pharmacogenomic implications of the CYP2C9, CYP2C19 and MDR1 polymorphisms in the efficacy of antiepileptic agents in primary epilepsy, Partnerships project, principal investigator Dr. Anca Buzoianu, dates 2007-2010
3. Pharmacogenomic impact of VKORC1 and CYP2C9 genetic polymorphisms on efficacy, safety and costs of oral anticoagulants, Partnerships project, principal investigator Dr. Anca Buzoianu, dates 2008-2011
4. Atherosclerosis and osteoporosis - from clinical observation to the genetic study. Evaluating common risk factors, K vitamin status and several genes in the pathogenesis of the two diseases, Partnerships project, principal investigator Dr. Daniela Fodor, dates 2008-2011
5. Massively parallel high-throughput sequencing for identifying microARNs differentially expressed between the metastatic site and origin, young research team project, principal investigator Dr. Ciprian Tomuleasa, dates 2015-2017
6. Rapide high resolution melting multiplex method for analysing FLT3, NPM1 and DNMT3A mutations in acute myeloid leukemia, experimental project, principal investigator Prof. Dr. Claudia Banescu, dates 2017-2018
7. Multidisciplinary platform for improving the regional institutional capacity in dermatooncology and oncological dermatopathology. PCCDI grant, principal investigator Prof. Dr. Rodica Cosgarea, dates 2018-2020
8. "BIOGENONCO – Biogenonco Knowledge transfer in clinical applications of biogenomics in oncology and related fields", POC grant, principal investigator Prof. Dr. Calin Cainap, dates 2016-2023
9. Improving the medical skills of professionals involved in the multidisciplinary management of rare diseases - ProGeneRare, project POCU/91/4/8/108073, principal investigator Dr. Mihai Ioana, dates: 2018-2020
10. Development of photochromic alternatives to dual in situ hybridization-immunohistochemistry testing for evaluation of breast and lymphoid tissue neoplasms, principal investigator Dr. Bogdan Fetica, dates 2020-2022
11. SARS-CoV-2 genome sequencing and phylogenetic analysis of circulating strains from Romania, SOL project, principal investigator Prof. Dr. Mihai Covasa, dates 2020-2021

12. The development of An Integrative Polygenic Score for acute myeloid leukemia prognostication, using complex genomic investigation, PCE project, principal investigator Prof. Dr. Claudia Banescu, dates 2021-2024

International projects – member

1. COST Action BM0902: Network of experts in the diagnosis of myeloproliferative disorders (MPD), project PC7, principal investigator Dr. Sylvie Hermouet, Nantes, France, dates: 2009-2013
2. MULTIDISCIPLINARY RESEARCH PROJECTS ON PERSONALISED MEDICINE – DEVELOPMENT OF CLINICAL SUPPORT TOOLS FOR PERSONALISED MEDICINE IMPLEMENTATION (IMAGene), ERA PerMed project, dates: 2022-2024, principal investigator Dr. Serena Oliveri, Milano, Italy

Annexe 2 Most relevant published articles

1. Neagoe CXR, Ionică M, Neagoe OC, **Trifa AP**. The Influence of Microbiota on Breast Cancer: A Review. *Cancers*. 2024; 16(20):3468, doi: 10.3390/cancers16203468. **IF = 4.5**
2. Cătană A, **Trifa AP**, Achimas-Cadariu PA, Bolba-Morar G, Lisencu C, Kutasi E, Chelaru VF, Muntean M, Martin DL, Antone NZ, Fetica B, Pop F, Militaru MS. Hereditary Breast Cancer in Romania-Molecular Particularities and Genetic Counseling Challenges in an Eastern European Country. *Biomedicines*, 2023;11(5):1386, doi: 10.3390/biomedicines11051386. **IF = 4.7**
3. Lighezan DL, Bojan AS, Iancu M, Pop RM, Gligor-Popa Ș, Tripon F, Cosma AS, Tomuleasa C, Dima D, Zdrenghea M, Fetica B, Ioniță I, Gaál IO, Vișan S, Mirea AM, Popp RA, Florea M, Aranicu C, Petrescu L, Pop IV, Bănescu C, **Trifa AP**. TET2 rs1548483 SNP Associating with Susceptibility to Molecularly Annotated Polycythemia Vera and Primary Myelofibrosis. *J Pers Med*. 2020 Dec 1;10(4):259. doi: 10.3390/jpm10040259. **IF = 4.433**
4. **Trifa AP**, Bănescu C, Bojan AS, Voina CM, Popa Ș, Vișan S, Ciubean AD, Tripon F, Dima D, Popov VM, Vesa ȘC, Andreescu M, Török-Vistai T, Mihăilă RG, Berbec N, Macarie I, Coliță A, Iordache M, Cătană AC, Farcaș MF, Tomuleasa C, Vasile K, Truică C, Todincă A, Pop-Muntean L, Manolache R, Bumbea H, Vlădăreanu AM, Gaman M, Ciufu CM, Popp RA. MECOM, HBS1L-MYB, THRB-RARB, JAK2, and TERT polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients. *Am J Hematol*. 2018 Jan;93(1):100-106. doi: 10.1002/ajh.24946. **IF = 6.137**
5. **Trifa AP**, Bănescu C, Tevet M, Bojan A, Dima D, Urian L, Török-Vistai T, Popov VM, Zdrenghea M, Petrov L, Vasilache A, Murat M, Georgescu D, Popescu M, Pătrinoiu O, Balea M, Costache R, Coleș E, Șaguna C, Berbec N, Vlădăreanu AM, Mihăilă RG, Bumbea H, Cucuianu A, Popp RA. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients. *Br J Haematol*. 2016 Jul;174(2):218-26. doi: 10.1111/bjh.14041. **IF = 5.67**
6. Bănescu C, Iancu M, **Trifa AP**, Căndea M, Benedek Lazar E, Moldovan VG, Duicu C, Tripon F, Crauciuc A, Dobreanu M. From Six Gene Polymorphisms of the Antioxidant System, Only GPX Pro198Leu and GSTP1 Ile105Val Modulate the Risk of Acute Myeloid Leukemia. *Oxid Med Cell Longev*. 2016;2016:2536705. doi: 10.1155/2016/2536705. **IF = 4.593**
7. Bănescu C, **Trifa AP**, Voidăzan S, Moldovan VG, Macarie I, Benedek Lazar E, Dima D, Duicu C, Dobreanu M. CAT, GPX1, MnSOD, GSTM1, GSTT1, and GSTP1 genetic polymorphisms in chronic myeloid leukemia: a case-control study. *Oxid Med Cell Longev*. 2014;2014:875861. doi: 10.1155/2014/875861. **IF = 3.516**
8. Trifa AP, Popp RA, Cucuianu A, Bănescu C, Tevet M, Martin B, Murat M, Vesa SC, Dima D, Căndea M, Militaru MS, Pop IV. CALR versus JAK2 mutated essential thrombocythaemia - a report on 141 patients. *Br J Haematol*. 2015 Jan;168(1):151-3. doi: 10.1111/bjh.13076. **IF = 5.812**
9. Buzoianu AD, **Trifa AP**, Mureșanu DF, Crișan S. Analysis of CYP2C9*2, CYP2C9*3 and VKORC1 -1639 G>A polymorphisms in a population from South-Eastern Europe. *J Cell Mol Med*. 2012 Dec;16(12):2919-24. doi: 10.1111/j.1582-4934.2012.01606.x. **IF = 4.753**
10. **Trifa AP**, Cucuianu A, Petrov L, Urian L, Militaru MS, Dima D, Pop IV, Popp RA. The G allele of the JAK2 rs10974944 SNP, part of JAK2 46/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms. *Ann Hematol*. 2010;89(10):979-83. **IF = 2.615**